



VACCINE DEVELOPMENT



STANDARD STEPS

- Exploratory Phase
- Pre Clinical Phase
- Investigational New Drug Application
- Phase I Vaccine Trials
- Phase II Vaccine Trials
- Phase III Vaccine Trials
- Phase IV Vaccine Trials



EXPLORATORY PHASE

- Basic laboratory research
 - Lasts 2-4 years
- Academic and governmental scientists identify natural or synthetic antigens
- Antigens include virus-like particles, weakened viruses or bacteria, weakened bacterial toxins, or other substances derived from pathogens



PRE CLINICAL PHASE

- Uses tissue-culture/cell-culture systems and animal testing to assess safety and ability to provoke an immune response
- Animal subjects may include mice and monkeys
- From this phase researchers get an idea of the cellular responses to expect in humans and a safe starting dose
- Many vaccines do not progress as they fail to produce the desired immune response
- This stage lasts 1-2 years



INVESTIGATIONAL NEW DRUG APPLICATION

- Sponsor submits an application for an IND
 - They describe the manufacturing and testing processes, summarize the laboratory reports, and describe the proposed study
- Once the IND is approved, the vaccine is subject to three phases of testing



PHASE I VACCINE TRIALS

- This first attempt to assess the vaccine in humans involves a small group of adults (20-80)
- If the vaccine is intended for children, researchers will first test adults, then gradually step down the age until they reach their target

Goals:

- Assess safety
- Determine the type and extent of immune response that the vaccine provokes



Phase II Vaccine Trials

- A larger group of several hundred individuals participates
- Some of the individuals may belong to groups at risk of acquiring the disease
 - These trials are randomized and well controlled, and include a placebo group



Phase II Vaccine Trials

Goals

- Vaccine's safety
- Immunogenicity
- Proposed doses
- Schedule of immunizations
- Method of delivery



Phase III Vaccine Trials

- Involve thousands to tens of thousands of people
- The experimental vaccine being is tested against a placebo (saline solution/vaccine for another disease, or some other substance)

Goal

- Assess vaccine safety and efficacy in a large group of people
- Rare side effects may show up in this group



Approval and Licensure

- After a successful Phase III trial, a Biologics License Application is submitted
- Factory inspection of vaccine production is done and if satisfactory, approval is granted



Phase IV trial

- This is an optional phase that drug companies may conduct after a vaccine is released
- The manufacturer may continue to test the vaccine for safety, efficacy, and other potential uses



VACCINE ADVERSE EVENT REPORTING SYSTEM

- Anyone, such as a parent, a health care provider, or friend of the patient, who suspects an association between a vaccination and an adverse event may report that event and information about it to VAERS
- The CDC then investigates the event and tries to find out whether the adverse event was in fact caused by the vaccination



CONCLUSION

- Vaccines are developed, tested, and regulated in a very similar manner to other drugs
- Vaccines are more thoroughly tested than non-vaccine drugs because the number of human subjects in vaccine clinical trials
- There is post-licensure monitoring of vaccines by regulatory bodies



VACCINE 101

Produced with support from

emergent
biosolutions[®]

Q²Solutions[®]

MSD
INVENTING FOR LIFE

nature

A graphic consisting of several concentric pentagonal shapes. The innermost shape is a bright yellow pentagon. It is surrounded by a ring of orange pentagons, which is further surrounded by a ring of yellow pentagons. The shapes are slightly offset from each other, creating a 3D, tunnel-like effect. The background of the graphic is a gradient of orange and yellow.



THANK YOU.